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Abstract
Background
The standard of care treatment for muscle-invasive bladder cancer (MIBC) is radical
cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the inabil-
ity to assess minimal residual disease (MRD) noninvasively limits our ability to offer bladder-
sparing treatment. Here, we sought to develop a liquid biopsy solution via urine tumor DNA
(utDNA) analysis.
Methods and findings
We applied urine Cancer Personalized Profiling by Deep Sequencing (uCAPP-Seq), a tar-
geted next-generation sequencing (NGS) method for detecting utDNA, to urine cell-free
DNA (cfDNA) samples acquired between April 2019 and November 2020 on the day of cura-
tive-intent radical cystectomy from 42 patients with localized bladder cancer. The average
age of patients was 69 years (range: 50 to 86), of whom 76% (32/42) were male, 64%
(27/42) were smokers, and 76% (32/42) had a confirmed diagnosis of MIBC. Among MIBC
patients, 59% (19/32) received neoadjuvant chemotherapy. utDNA variant calling was
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performed noninvasively without prior sequencing of tumor tissue. The overall utDNA level
for each patient was represented by the non-silent mutation with the highest variant allele
fraction after removing germline variants. Urine was similarly analyzed from 15 healthy
adults. utDNA analysis revealed a median utDNA level of 0% in healthy adults and 2.4% in
bladder cancer patients. When patients were classified as those who had residual disease
detected in their surgical sample (n = 16) compared to those who achieved a pathologic
complete response (pCR; n = 26), median utDNA levels were 4.3% vs. 0%, respectively (p =
0.002). Using an optimal utDNA threshold to define MRD detection, positive utDNA MRD
detection was highly correlated with the absence of pCR (p < 0.001) with a sensitivity of
81% and specificity of 81%. Leave-one-out cross-validation applied to the prediction of path-
ologic response based on utDNA MRD detection in our cohort yielded a highly significant
accuracy of 81% (p = 0.007). Moreover, utDNA MRD–positive patients exhibited signifi-
cantly worse progression-free survival (PFS; HR = 7.4; 95% CI: 1.4–38.9; p = 0.02) com-
pared to utDNA MRD–negative patients. Concordance between urine- and tumor-derived
mutations, determined in 5 MIBC patients, was 85%. Tumor mutational burden (TMB) in
utDNA MRD–positive patients was inferred from the number of non-silent mutations
detected in urine cfDNA by applying a linear relationship derived from The Cancer Genome
Atlas (TCGA) whole exome sequencing of 409 MIBC tumors. We suggest that about 58% of
these patients with high inferred TMB might have been candidates for treatment with early
immune checkpoint blockade. Study limitations included an analysis restricted only to sin-
gle-nucleotide variants (SNVs), survival differences diminished by surgery, and a low num-
ber of DNA damage response (DRR) mutations detected after neoadjuvant chemotherapy
at the MRD time point.
Conclusions
utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer corre-
lated significantly with pathologic response, which may help select patients for bladder-spar-
ing treatment. utDNA MRD detection also correlated significantly with PFS. Furthermore,
utDNA can be used to noninvasively infer TMB, which could facilitate personalized immuno-
therapy for bladder cancer in the future.
Author summary
Why was this study done?
• The standard of care for muscle-invasive bladder cancer (MIBC) is neoadjuvant chemo-
therapy followed by radical cystectomy, which significantly impacts quality of life.
• The inability to assess minimal residual disease (MRD) noninvasively limits our ability
to offer bladder-sparing treatment.
• We determine if urine tumor DNA (utDNA) detection just prior to radical cystectomy
can predict pathologic complete response (pCR) and differences in survival outcomes.
• We determine if utDNA analysis can identify patients who are candidates for early
immune checkpoint blockade.
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What did the researchers do and find?
• We applied urine Cancer Personalized Profiling by Deep Sequencing (uCAPP-Seq) to
urine cell-free DNA (cfDNA) samples acquired on the day of curative-intent radical
cystectomy from 42 patients with localized bladder cancer.
• Positive utDNA MRD detection was highly correlated with the absence of pCR (p<
0.001) with a sensitivity of 81% and specificity of 81%.
• utDNA MRD–positive patients exhibited significantly worse progression-free survival
(PFS) compared to utDNA MRD–negative patients (HR = 7.4; 95% CI: 1.4–38.9; p =
0.02).
• Patients with high TMB inferred from urine might have been candidates for early treat-
ment with immune checkpoint blockade.
What do these findings mean?
• utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer
correlated significantly with pathologic response, which may help select patients for
bladder-sparing treatment.
• utDNA can be used to noninvasively infer TMB, which could facilitate personalized
immunotherapy for bladder cancer patients in the future.
Introduction
In the United States of America, bladder cancer is the sixth most commonly diagnosed cancer
overall and the fourth most commonly diagnosed malignancy in men [1]. Clinical manage-
ment is largely dependent on the extent to which the tumor penetrates the bladder wall at time
of presentation [2]. Approximately 70% of patients initially present with non–muscle-invasive
bladder cancer (NMIBC) [3]. These patients are typically treated with transurethral resection
of bladder tumor alone or in conjunction with intravesical therapy. While 5-year survival rates
for NMIBC are favorable, patients carry a high risk of recurrence or progression to more
advanced stages of disease [4]. Therefore, these patients require frequent monitoring with
invasive cystoscopic examinations. As a result, bladder cancer has been found to have the high-
est lifetime cost per patient of any malignancy [5,6].
Approximately 25% of bladder cancer patients present with organ-confined muscle-inva-
sive bladder cancer (MIBC), characterized by tumor that extends to the underlying detrusor
muscle [7]. The standard of care treatment recommendation for both MIBC and recurrent/
progressive NMIBC after appropriate intravesical therapy is radical cystectomy with urinary
diversion, a significant surgical procedure with a major impact on quality of life [8,9]. For
MIBC patients, this is often preceded by cisplatin-based neoadjuvant chemotherapy [10].
Despite these aggressive measures, the overall 5-year survival for MIBC is still only about 50%,
and the recurrence risk is substantial [11].
Pathologic response is a strong prognostic indicator of long-term survival after radical
cystectomy [12,13]. Based on evaluation of the radical cystectomy specimen, approximately
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35% of patients will achieve a pathologic complete response (pCR) following neoadjuvant
treatment [10,14]. Retrospective data support the idea that some patients who achieve an excel-
lent response to neoadjuvant treatment may be able to safely forgo radical cystectomy [15]. If
patients likely to have achieved a pCR could be better identified prospectively, this could sup-
port personalized care, enabling some patients to avoid the life-altering morbidity of urinary
diversion and potential mortality from operative complications [8].
Cystoscopy, while considered invasive and uncomfortable, can be used to evaluate tumor
response to neoadjuvant chemotherapy or chemoradiation. However, cystoscopy prior to radi-
cal cystectomy frequently under-stages disease burden [16,17], creating a major barrier to test-
ing and implementing personalized bladder-sparing treatment paradigms. Furthermore,
patients managed with bladder-sparing treatment remain at significant risk for recurrence
[15], thus requiring frequent monitoring with invasive cystoscopy [17]. Therefore, it is critical
that we advance our standard of care to enable improved accuracy and reduced morbidity
when assessing and monitoring localized bladder cancer.
Plasma- and urine-based biomarkers present a promising opportunity for noninvasive
management of localized bladder cancer [18,19]. Cancer Personalized Profiling by Deep
Sequencing (CAPP-Seq) with integrated digital error suppression (iDES) is an ultrasensitive
method of high-throughput sequencing used to detect circulating tumor DNA (ctDNA)
[20,21]. In recent years, the utility of CAPP-Seq with iDES in the detection of minimal residual
disease (MRD) has been validated in a variety of tumor types [22–28]. Urine tumor DNA
(utDNA) analysis with an adapted version of CAPP-Seq, called urine Cancer Personalized Pro-
filing by Deep Sequencing (uCAPP-Seq), was recently shown to be a highly sensitive urine-
based approach for monitoring NMIBC patients treated conservatively with modalities other
than radical cystectomy [28].
Here, we seek to validate uCAPP-Seq by applying it to urine collected from a largely MIBC
cohort with every patient treated with curative-intent radical cystectomy. We determine if
utDNA variant calling without prior sequencing of tumor tissue using urine samples collected
just prior to radical cystectomy can predict pathologic staging and differences in survival out-
comes, namely progression-free survival (PFS) and overall survival (OS). Furthermore, we
address the hypothesis that utDNA can be used to infer tumor mutational burden (TMB) and
identify actionable mutations, which could potentially inform personalized adjuvant treatment




Our cohort study was designed to determine whether utDNA on the day of radical cystectomy
correlates with pathologic response and detects MRD in patients with localized bladder cancer.
Thus, we enrolled 48 patients with localized bladder cancer undergoing curative-intent radical
cystectomy and 27 healthy adults at Washington University from April 2019 to November
2020 (Fig 1). Patients and healthy adults were enrolled onto institutionalized human research
protocols approved by the Human Research Protection Office at Washington University
(Institutional Review Board [IRB] #201411135 and IRB #201903142, respectively) and pro-
vided written informed consent to the collection and molecular analysis of biological speci-
mens (urine, blood, and/or tumor tissue) in accordance with the Declaration of Helsinki. The
protocol can be accessed on ClinicalTrials.gov (NCT04354064). We profiled and analyzed
paired urine and blood samples acquired on the day of radical cystectomy from 42 consented
patients (S1 Table). Patients were excluded if they had a blood sample without urine, a urine
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sample without blood, or a history of immunosuppression for a solid organ transplant, which
has been shown to confound the detection of tumor DNA [29,30]. In 2 patients, we addition-
ally obtained serial urine samples prior to and during neoadjuvant chemotherapy. Patients
continued clinical follow-up after radical cystectomy as per the standard of care, and the man-
aging clinicians were blinded to the utDNA data. Paired urine and blood samples were also
collected from 15 healthy adults for variant calling analysis. Urine samples without blood were
collected from another 12 healthy adults and used to reduce stereotypical base substitution
errors for our serial mutation tracking and TMB analyses (see Methods: utDNA monitoring
during neoadjuvant chemotherapy and Methods: Inferring TMB from utDNA analysis) [21].
This study is reported as per the Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) guideline (S1 Checklist).
Eligibility criteria
Patients were required to have a histologic or cytologic diagnosis of bladder cancer amenable
for radical cystectomy. MIBC was defined as invasive urothelial carcinoma staged at least T2
or higher (i.e., invasion of the detrusor muscle) found on transurethral resection of bladder
tumor or radiographically determined by a board-certified urologic oncologist and/or medical
oncologist. In some equivocal cases, a multidisciplinary tumor board assessment was required
to determine a case for surgical resection. The primary bladder cancer could have been previ-
ously treated with intravesical agents such as Bacillus Calmette–Guérin (BCG), valrubicin, or
gemcitabine. Some cases of T1 disease were also allowed into the study. The decision to
Fig 1. Patient enrollment and sample collection for utDNA MRD analysis. Patients with localized bladder cancer who were candidates for radical cystectomy were
enrolled onto this study, as were healthy adult donors. Biofluid samples were then collected for utDNA analysis as shown in the schema. MRD, minimal residual
disease; pCR, pathologic complete response; uCAPP-Seq, urine Cancer Personalized Profiling by Deep Sequencing; utDNA, urine tumor DNA.
https://doi.org/10.1371/journal.pmed.1003732.g001
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proceed with cystectomy in cases of T1 disease was made by the patient and the treating physi-
cian, often in collaboration with a multidisciplinary tumor board. These cases were resistant to
prior intravesical chemotherapy and/or considered at high risk for progression based on path-
ological features. We sought to include any bladder cancer patient with an indication for radi-
cal cystectomy into our study in order to extend the application of predicting pathologic
response based on utDNA to a broader, real-world patient population that could potentially
benefit from bladder-sparing treatment. Patients with any other known active cancer diagno-
ses other than bladder cancer were excluded from enrollment. Electronic medical records
were reviewed for each patient to ensure that they met the eligibility criteria for this study.
Pathologic response assessment
All surgical samples were sampled consistently following standard collection, handling, and
submission procedures. The resected surgical specimens (e.g., bladder, prostate, and pelvic
lymph nodes) were submitted to the Pathology Department at Washington University for
review by a genitourinary surgical pathologist. Based on the eligibility criteria used in an
enrolling multi-institutional Alliance trial on nonmetastatic MIBC (NCT03609216) [31], we
defined pCR as stages T0, Tis, and/or Ta with no involved lymph nodes in the surgical speci-
men. This is consistent with the definition used in other solid tumor malignancies as well,
including breast cancer [32]. An absence of pCR was defined as stages T1 to T4 or evidence of
nodal/metastatic disease in the surgical specimen based on the American Joint Committee on
Cancer (AJCC) 8th edition criteria [33].
Urine cell-free DNA stability in the presence of EDTA
Multiple urine samples from a healthy adult were used to test the stability of urine cell-free
DNA (cfDNA) in the presence of EDTA (S1 Fig). Pooled urine from this individual was ali-
quoted into 4 pairs of two 10-mL replicates, each pair testing urine cfDNA stability at different
time points (0, 1, 3, and 7 days), with or without EDTA. Thus, 10 mM EDTA was added to one
aliquot, and an equal amount of nuclease-free water was added to the other aliquot. The urine
samples were then stored at room temperature (approximately 20˚C) for these different
lengths of times. After each time point, the urine was centrifuged, and the supernatant was
transferred to fresh tubes and stored at −80˚C. Urine cfDNA was isolated from the stored
supernatant. Urine cfDNA was purified further by AMPure XP (Beckman Coulter Life Sci-
ences, Indianapolis, Indiana, USA) magnetic bead–based size selection. We removed genomic
DNA using 0.6× concentration of beads, followed by 1.8× concentration of beads to capture
the remaining urine cfDNA. Isolated urine cfDNA was analyzed by electropherogram
obtained using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California,
USA).
Comparison of urine cell-free DNA fragmentation with in silico size
selection
We compared 2 different methodologies for optimizing the detection of variants prior to urine
cfDNA library preparation. Urine cfDNA was isolated with Q-sepharose from 4 MIBC patients,
as described in the “Urine cell-free DNA isolation and quantification” section below, and pro-
cessed using 1 of 2 methodologies: standard whole urine cfDNA fragmentation or in vitro size
selection (S2 Fig). For the fragmentation method, we acoustically sheared urine cfDNA to
approximately 200-bp fragments using a LE220 focused ultrasonicator (Covaris, Woburn, Mas-
sachusetts, USA). For the in vitro size selection protocol, we used AMPure XP magnetic beads
to enrich cfDNA fragments ranging from 70 to 450 bp before sequencing. Following each
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method, we prepared sequencing libraries per the uCAPP-Seq protocol. We compared the
median deduplicated depth (S3A Fig), number of non-silent mutations detected (S3B Fig), and
variant allele fraction levels (S3C Fig) among the common non-silent mutations found by both
methodologies. Only variants with duplex support were considered in this analysis.
Biological specimen collection and processing
Urine samples, ranging in volume between 22 and 90 mL, from 42 localized bladder cancer
patients were collected in sterile vials containing 2 mL of 0.5 M EDTA in the preoperative set-
ting. Samples were centrifuged at 2,000 g for 10 minutes at room temperature (approximately
20˚C). After centrifugation, supernatant was transferred to a fresh tube and then stored at
−80˚C. Along with urine, patient blood was collected in K2-EDTA Vacutainer tubes (Becton
Dickinson, Franklin Lakes, New Jersey, USA), from which germline plasma-depleted whole
blood was collected and stored at −80˚C as previously described [23,34]. Tumor tissue was also
available for sequencing from 5 patients with no antecedent systemic therapy. Tumor tissue
was acquired either from the radical cystectomy or transurethral resection of bladder tumor
and was either stored fresh-frozen or processed as formalin-fixed paraffin-embedded samples.
Urine cell-free DNA isolation and quantification
Urine cfDNA was prepared from 22 to 90 mL of urine with Q-sepharose resin slurry (GE
Healthcare, Chicago, Illinois, USA) at a ratio of 10 μL slurry per mL of urine and mixed as pre-
viously described [28,35]. After 30 minutes, the urine/resin mixture was centrifuged for 10
minutes at 1,800 g. The supernatant was discarded, and resin was washed twice with 0.3 M
LiCl/10 mM sodium acetate (pH 5.5), applying 2 mL per 100-μL resin. The resin was then
transferred to a Micro Bio-Spin column (Bio-Rad, Hercules, California, USA), and the bound
material was eluted by adding 3 separate 670-μL aliquots of 2 M LiCl/10 mM sodium acetate
(pH 5.5). Next, the eluates were combined in 70% ethanol and passed over a QIAquick column
(Qiagen, Hilden, Germany). The column was washed with 5 mL of 2 M LiCl in 70% ethanol,
followed by 5 mL of 75 mM potassium acetate (pH 5.5) in 80% ethanol. We removed residual
liquid by centrifuging the columns at 20,000 g for 3 minutes. Finally, bound DNA was eluted
into 50 μL of nuclease-free water or 10 mM Tris-Cl (pH 8.5). DNA concentrations were mea-
sured using a Qubit dsDNA HS Assay Kit and Qubit 4.0 Fluorometer (Thermo Fisher Scien-
tific, Waltham, Massachusetts, USA).
Germline and tumor DNA isolation and quantification
The QIAamp DNA Micro Kit (Qiagen) was employed to extract germline DNA from 100 μL
of plasma-depleted whole blood or tumor DNA from freshly frozen tumor tissue. The AllPrep
DNA/RNA FFPE Kit (Qiagen) was used to extract DNA from one tumor-embedded paraffin
block according to the manufacturer’s instructions. DNA was then quantified using the Qubit
assay per the manufacturer’s recommendations (Thermo Fisher Scientific).
DNA library construction and sequencing
Urine cfDNA was fragmented to approximately 200-bp size, while germline DNA and tumor
DNA were sheared to approximately 250-bp size prior to library preparation using a LE220
Focused Ultrasonicator (Covaris). All urine cfDNA and germline DNA libraries were prepared
using the Kapa HyperPrep Kit with custom sequencing adapters containing demultiplexing,
deduplicating, and duplex barcodes [21]. Minimum inputs of 32 ng were used for each library
preparation reaction. Targeted hybrid-capture was performed per the uCAPP-Seq protocol
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[28] with the following modifications: For urine cfDNA, 3 or 4 samples were captured with the
custom bladder cancer selector panel (S2 and S3 Tables), while 6-plex captures and 12-plex
captures were performed for tumor and germline samples, respectively. Libraries were
sequenced on an Illumina HiSeq 4000 with 2 × 150 bp paired-end reads. Sequencing quality
control metrics including deduplicated depth, on-target rate, fragment size, and duplex recovery
rate were reviewed (S4–S6 Tables). We sequenced urine cfDNA from localized bladder cancer
patients and healthy donors to a median deduplicated depth of 811×, while germline DNA and
tumor DNA were sequenced to a median deduplicated depth of 781× and 1917×, respectively
(S4–S6 Tables). Sequences were analyzed for single-nucleotide variants (SNVs) using the
uCAPP-seq bioinformatics pipeline with error suppression [20,21]. Briefly, sequencing reads
were demultiplexed using sample-level index barcodes, mapped to the reference genome
GRCh37/hg19 (February 2009), filtered for properly paired reads, filtered for bases with Phred
quality score�30, and deduplicated using unique molecular barcodes. The molecular barcod-
ing strategy enabled the identification of duplex-supported reads (S4 and S5 Tables).
Duplex-supported variant calling for utDNA MRD analysis
utDNA was assessed by deep targeted sequencing of preoperative urine-derived cfDNA. Nota-
bly, utDNA analysis from urine was performed without prior sequencing of tumor tissue (i.e.,
tumor-naive approach). We used a focused MRD gene panel encompassing 49 consensus
driver genes frequently mutated in bladder cancer [36–40] (S2 Table). For SNV calling from
urine, we utilized the CAPP-Seq with iDES pipeline [20,21,28] and filtered out any mutation
also detected in the matched germline DNA sample. SNVs with population frequency >0.0001
in the Genome Aggregation Database (gnomAD) were also filtered out [41]. The identified
variants were further annotated with ANNOVAR [42] for mutation type, associated gene
name, location with respect to associated gene, and amino acid change when relevant, and
only those with duplex support were considered further for the MRD analysis. These duplex-
supported SNVs were then categorized as silent versus non-silent mutations. Silent mutations
included the following: exonic synonymous mutations, intronic mutations (except in
PLEKHS1), promoter mutations (except in TERT), 50 UTR mutations (except in TBC1D12),
and 30 UTR mutations. Non-silent mutations included the following: exonic nonsynonymous
mutations, splicing mutations, stop codon mutations, and the aforementioned exceptions
based on evidence in the literature [28,36,38]. Overall utDNA levels were finally quantified as
the highest variant allele fraction among non-silent mutations with duplex support detected by
CAPP-Seq per urine sample. We required duplex-supported reads in our MRD variant calling
approach in order to significantly reduce the background error rate as previously described
[21].
We bioinformatically tested our MRD gene panel, spanning 145 kb and consisting of 49
consensus driver genes, on 2 whole exome sequencing datasets of pretreatment MIBC tumors:
from The Cancer Genome Atlas (TCGA, n = 409) and from both the Dana-Farber Cancer
Institute and Memorial Sloan Kettering Cancer Center (DFCI/MSKCC, n = 50) [38,39]. Con-
cordance between urine cfDNA variants and tumor tissue variants was also assessed in 5
patients with paired urine and tumor tissue available. Combined lists of non-silent mutations
with duplex support identified in urine or tumor were queried among non-reference variants
present in tumor and urine, respectively (S7 Table).
utDNA monitoring during neoadjuvant chemotherapy
We also obtained serial urine samples from 2 patients prior to starting neoadjuvant chemo-
therapy, while on neoadjuvant chemotherapy, and on the day of surgery. While duplex-
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supported reads were not required for variant monitoring, we utilized background polishing
using 12 healthy donor urine samples to reduce stereotypical base substitution errors as previ-
ously described [21,28]. We combined all the mutations detected after iDES and then moni-
tored each mutation at every time point using the CAPP-Seq bioinformatic pipeline as
previously described [20,21,28].
Inferring TMB from utDNA analysis
TMB was defined as the total number of non-silent mutations in the whole exome. We utilized
an expanded custom hybrid-capture panel (called “TMB panel” in this study) to infer TMB in
our cohort. The TMB panel is 387 kb in size, covers 536 genes, and spans all regions in the previ-
ously published uCAPP-Seq panel [28] along with canonical DNA damage response (DDR)
genes [43] (S3 Table). To establish the relationship between the number of mutations observed
in our uCAPP-Seq TMB panel to exome-wide TMB in bladder cancer, we downloaded somatic
variant calls from 409 MIBC tumors that underwent whole exome sequencing by TCGA from
https://www.cbioportal.org/ [44]. Non-silent mutations in TCGA whole exome sequencing data
were defined as the following mutation types: frameshift mutation (deletion/insertion), missense
mutation, nonsense mutation, nonstop mutation, and splice mutation (region/site). We filtered
out in-frame mutations (deletion/insertion) and mutations in the 30 flank, 30 UTR, 50 flank, 50
UTR, and intronic regions. TMB panel versus whole exome sequencing mutational loads were
compared using Pearson correlation. We used this simple linear regression equation to infer the
TMB levels from urine for all utDNA MRD–positive patients in our cohort, which we applied
after accounting for potential dropout in utDNA results as previously described [20,21].
Identifying actionable mutations from utDNA analysis
utDNA variants detected within our MRD gene panel after uCAPP-Seq were queried in the
OncoKB database [45] to identify patients who may harbor a clinically actionable mutation
(S8 Table). Level 3A evidence denotes compelling clinical data supporting this mutation as a
biomarker predictive of response to a drug in bladder cancer [45]. Level 3B evidence denotes a
mutation as a biomarker predictive of response to a Food and Drug Administration (FDA)-
approved drug or an investigational drug in another malignancy [45].
Power and statistical analyses
Previous clinical studies in MIBC have shown that patients who do not attain a pCR experi-
ence significantly increased risk of progression and death due to residual disease compared to
patients with pCR [12,13]. Thus, we hypothesized a large difference in utDNA levels between
patients with pCR compared to those without pCR. Based on a large effect size estimated by
Cohen’s f = 0.5, we require at least 14 subjects in each group to detect a difference with 80%
power, as determined by a 1-way ANOVA with a significance level of 0.05. Therefore, we col-
lected paired urine and blood samples from healthy donors and bladder cancer patients with
enrollment until we reached at least 14 subjects for each subgroup of the analysis.
Patient characteristics were statistically compared between groups of pCR and no pCR
patients using Fisher exact test for categorical variables, Student t test for normally distributed
continuous variables, and Mann–Whitney U test for non-normally distributed continuous
variables. Normality was assessed using the Shapiro–Wilk test with a 0.05 significance level.
utDNA levels in each group of cohort subjects represented distributions of continuous vari-
ables and were compared without assuming normality using the Mann–Whitney U test with a
0.017 significance level, adjusted with a Bonferroni correction for comparison of 3 groups. For
our analysis restricted to patients who received neoadjuvant chemotherapy, utDNA levels
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were compared using the Mann–Whitney U test with a 0.05 significance level. To assess
utDNA as a classifier of pathologic response, we performed receiver operating characteristic
(ROC) analysis and measured the area under the curve. MRD detection was determined by
identifying the utDNA level threshold on the ROC curve that classified patients with no pCR
versus healthy adults with the highest Youden index. Then, we applied this optimal threshold
(utDNA level of 2.3%) to establish utDNA MRD detection among patients with pCR or no
pCR. Fisher exact test with a 0.017 significance level, adjusted with a Bonferroni correction for
comparison of multiple proportions, was used to assess the association between utDNA MRD
detection and pathologic response.
Leave-one-out cross-validation was performed in R using the caret package’s LOOCV
method to assess the generalizability of our utDNA MRD predictor to independent data. This
was done by generating a univariate logistic regression to predict pCR based on utDNA MRD
from k-1 samples and applying this model to predict the kth sample over k iterations. Accuracy
of prediction was determined using the confusionMatrix function with p-value computed
using the 1-sided binomial test function.
Kaplan–Meier analysis with log-rank test was performed for PFS and OS based on follow-
up within 200 days of surgery. Multivariate logistic regression analysis was performed using
the glm function in R for predicting the absence of pCR using the following covariates: utDNA
MRD detection, smoking status, neoadjuvant chemotherapy, staging at the time of diagnosis
or transurethral resection of bladder tumor, age (continuous variable), sex, ethnicity, and his-
tology. All statistical analyses were performed using R v3.6.3 (http://www.r-project.org)
through the RStudio v1.1.463 environment (RStudio, Boston, Massachusetts, USA) and Prism
8 (GraphPad Software, San Diego, California, USA).
Results
Cohort characteristics
We profiled urine cfDNA and matched peripheral blood germline samples collected from 42
patients with localized bladder cancer and 15 healthy donors (Fig 2A). Our bladder cancer
cohort was comprised of 76% (32/42) males and 64% (27/42) smokers, and the average age was
69 years. A total of 76% (32/42) of patients had a confirmed diagnosis of MIBC, 59% of whom
received neoadjuvant chemotherapy, while the remaining 24% had high-risk NMIBC (Table 1,
S1 Table). No patients had any other known active cancer diagnoses at the time of surgery.
Optimization of urine cell-free DNA processing
All patient urine samples were collected preoperatively just prior to the time of radical cystect-
omy with the addition of EDTA to preserve the stability of urine cfDNA at room temperature
(S1 Fig). We also compared 2 different methodologies of urine cfDNA processing prior to
urine cfDNA library preparation: standard protocol of acoustic fragmentation versus in vitro
size selection of smaller fragments (S2 Fig). Although we achieved significantly higher median
deduplicated depth (S3A Fig) with the size selection method compared to the fragmentation
protocol in 4 MIBC patients, there were no significant differences in the number of non-silent
mutations detected (S3B Fig) or in the variant allele fraction levels among common non-silent
mutations (S3C Fig) detected by the 2 techniques.
Development and validation of MRD gene panel for utDNA detection
We used a noninvasive approach without prior sequencing of tumor tissue using uCAPP-Seq
to profile mutations detected in urine. For a targeted evaluation of defined consensus regions,
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we used a focused MRD gene panel encompassing 49 consensus driver genes frequently
mutated in bladder cancer (S2 Table). These driver genes were selected from previous litera-
ture with comprehensive genomic characterization of bladder cancer [36–40]. In silico appli-
cation of this MRD gene panel to 409 MIBC tumors profiled by TCGA and 50 MIBC tumors
profiled by DFCI/MSKCC predicted that 96% of patients had mutations detectable within the
gene panel space [38,39] with a median of 5 mutations (non-silent and silent) detected per
patient (Fig 2B).
We then tested the MRD panel for concordance of mutations detected in urine compared
to tumor tissue. Five patients had paired urine and tumor tissue available for uCAPP-Seq
using the MRD panel. Three patients had radical cystectomy tissue available, while 2 had trans-
urethral resection of bladder tumor tissue from the time of diagnosis. Of note, none of these
tissue samples had been affected by neoadjuvant chemotherapy. The concordance between
urine- and tumor-derived mutations, determined in these 5 localized bladder cancer patients
by uCAPP-Seq, was 85% (S7 Table).
Non-silent mutations classify pathologic response
In our cohort, 38% (16/42) of patients achieved a pCR (n = 16), while 62% (26/42) had residual
disease detected in their surgical sample (denoted as no pCR; n = 26). There were no signifi-
cant differences between pCR and no pCR patients with regard to age, sex, ethnicity, smoking
status, pretreatment tumor stage, receipt of neoadjuvant chemotherapy, or tumor histology
(S9 Table). Furthermore, there was no significant difference in the concentration of urine
cfDNA obtained between the 2 groups of patients.
We applied the MRD gene panel to the preoperative urine of these patients and detected a
total of 52 non-silent mutations and 17 silent mutations (S8 Table). To have high confidence
in our noninvasive variant calling, we only considered mutations detected in urine cfDNA
with duplex support and with no read support in matched peripheral blood germline samples.
Using the mutation with the highest variant allele fraction to represent the utDNA level, we
compared the strength of association between pathologic response and utDNA detected from
either non-silent or silent mutations. The ROC curve for non-silent mutations achieved a sen-
sitivity of 81% and specificity of 81% (AUC = 0.78; 95% CI: 0.62 to 0.93), whereas the ROC
curve for silent mutations achieved a sensitivity of only 12% (AUC = 0.53; 95% CI: 0.35 to
0.71) (Fig 2C). These results indicate that non-silent mutations classify pathologic response
much more accurately than silent mutations, potentially because silent mutations are more
likely to represent background field effect [18,46].
Consistent with increased background noise due to field effect, we observed that variant
calling of non-silent, duplex-supported mutations within an expanded panel of 536 genes
Fig 2. uCAPP-Seq application of MRD gene panel to urine samples. (A) Study schema. Urine and blood samples from 42 localized bladder
cancer patients scheduled for radical cystectomy and 15 healthy adults were profiled by uCAPP-Seq. Samples from localized bladder cancer
patients were collected preoperatively on the day of surgery. Sequencing libraries were prepared from urine cfDNA and peripheral blood
germline DNA. utDNA analysis and results were primarily correlated with pathologic response in this study. (B) In silico application of the
MRD panel, consisting of 49 consensus driver genes, to MIBC cases characterized by TCGA (n = 409) and DFCI/MSKCC (n = 50). A median of
5 mutations (silent and non-silent) per patient was detected in both datasets as indicated. (C) ROC curve classified pCR (n = 16) from no pCR
(n = 26) patients by utDNA level, represented by the mutation with highest VAF. utDNA level derived from non-silent mutations (red curve)
classified pathologic response significantly more accurately than silent mutations (blue curve). (D) Co-mutation plot showing non-silent driver
mutations (with duplex support) detected in the urine of each patient with no pCR, patient with pCR, and healthy adult (bottom heatmap).
utDNA level per variant is depicted within the heatmap, while the conglomerate level per subject is represented by the bar graph. Key patient
characteristics are represented by the top heatmap. AUC, area under the curve; cfDNA, cell-free DNA; DFCI/MSKCC, Dana-Farber Cancer
Institute and Memorial Sloan Kettering Cancer Center; MIBC, muscle-invasive bladder cancer; MRD, minimal residual disease; NGS, next-
generation sequencing; pCR, pathologic complete response; ROC, receiver operating characteristic; Sn, sensitivity; Sp, specificity; TCGA, The
Cancer Genome Atlas; uCAPP-Seq, urine Cancer Personalized Profiling by Deep Sequencing; utDNA, urine tumor DNA; VAF, variant allele
fraction.
https://doi.org/10.1371/journal.pmed.1003732.g002
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Table 1. Characteristics of enrolled bladder cancer patients and healthy adults.
Characteristics Number Percentage












Pack-years 20 (0–56) _













Treatment switchb 1 5
Unknown regimen type 2 11
No 23 55









Age (years) 31 (20–65) _
aT staging was performed at the time of pretreatment TURBT using the AJCC 8 criteria.
bTreatment switch: 1 cycle of carboplatin/paclitaxel and 3 cycles of gemcitabine/carboplatin (switched due to
cutaneous reaction to paclitaxel).
cpCR was defined as T0N0, TaN0, or TisN0 (see Methods: Pathologic response assessment).
dUrine and peripheral blood samples from 15 healthy adults were collected to assess specificity of the variant calling
approach (see Figs 1 and 2A and Methods: Study design). Urine samples were collected from another 12 healthy
adults to use for iDES (see Fig 1, Methods: Study design, and Methods: utDNA monitoring during neoadjuvant
chemotherapy).
AJCC 8, American Joint Committee on Cancer 8th edition; ddMVAC, dose-dense methotrexate, vinblastine,
doxorubicin, and cisplatin; iDES, integrated digital error suppression; pCR, pathologic complete response; TURBT,
transurethral resection of bladder tumor.
https://doi.org/10.1371/journal.pmed.1003732.t001
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covering 387 kb of genomic space did not offer increased sensitivity and had inferior specific-
ity (S4 Fig). The sensitivity only increased when variant calling was expanded to all duplex-
supported mutations (silent or non-silent) within the expanded gene panel, but this also came
at the expense of lower specificity. As a result, variant calling of non-silent, duplex-supported
mutations within the driver gene-focused MRD panel yielded the best balance of sensitivity
and specificity for classifying pathologic response in our cohort.
No pCR is associated with higher utDNA levels than pCR
Focusing only on non-silent mutations in the MRD gene panel, we observed that patients with
no pCR carried significantly more mutations (median of 2 mutations per patient) than patients
with pCR (median of 0 mutations per patient). Urine cfDNA harbored a lower median num-
ber of mutations at the MRD time point than the aforementioned TCGA and DFCI/MSKCC
studies [38,39], where tumor next-generation sequencing (NGS) was performed prior to any
treatment. This decrease is consistent with prior ctDNA MRD studies in other solid tumor
malignancies [23,25,47]. TERT and TP53 were the most commonly altered genes detected in
urine cfDNA across our 42 patient cohort (Fig 2D), consistent with the most commonly
mutated genes in MIBC patients reported by TCGA and MSKCC [38,48]. TERT promoter and
TP53mutations were detected in 24% (10/42) and 21% (9/42) of cases, respectively. uCAPP-
Seq was also performed on 15 healthy adults to query the specificity of our MRD gene panel
variant data. Only 2 mutations, one in the PLEKHS1 intron and the other in ATM, were identi-
fied among these 15 healthy adults.
Moving forward in our analysis, we chose to represent a utDNA level for each patient based
on the non-silent mutation with the highest variant allele fraction. Comparing utDNA levels
between the groups, patients with no pCR had a significantly higher median utDNA level com-
pared to patients with pCR (4.3% versus 0%, p = 0.002) and healthy adults (4.3% versus 0%,
p< 0.001) (Fig 3A). In contrast, there was no difference in the median utDNA levels between
healthy adults and patients with pCR (0% versus 0%, p = 0.2), implying that patients with pCR
have similarly low biological background of urine variants as normal healthy adults. We then
used variant data from the healthy adults to determine the optimal utDNA level threshold that
classifies localized bladder cancer patients from healthy adults. Based on an ROC curve, this
threshold was determined to be 2.3%, which classified patients with no pCR from healthy
adults with a sensitivity of 81% and specificity of 100% (AUC = 0.91; 95% CI: 0.81 to 1.0) (Fig
3B). Therefore, patients with a utDNA level above or below this threshold were designated as
utDNA MRD positive or negative, respectively.
The proportion of utDNA MRD–positive patients varied among patients with pCR,
patients with no pCR, and healthy adults (Fig 3C). A total of 21 out of 26 (81%) patients with
no pCR were utDNA MRD positive. Positive utDNA MRD detection was significantly associ-
ated with no pCR by Fisher exact test (p< 0.001) with a sensitivity of 81% and specificity of
81%. Positive predictive value (PPV) and negative predictive value (NPV) were 88% (21/24)
and 72% (13/18), respectively. A multivariate logistic regression analysis was performed
including 8 covariates to predict the absence of pCR: utDNA MRD detection, smoking status,
administration of neoadjuvant chemotherapy, AJCC 8 tumor stage, age (continuous variable),
sex, ethnicity, and histology (Fig 3D). This further corroborated utDNA MRD detection as the
sole predictor of pathologic response (p = 0.003, odds ratio = 54.2), which established a clear
separation between patients with pCR and patients with no pCR (S10 Table). Using utDNA
MRD to predict pCR in a univariate logistic regression, we also applied leave-one-out cross-
validation. Cross-validation revealed a highly significant accuracy of 81% (p = 0.007), which
suggests that our prediction model generalizes well to independent data.
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Fig 3. utDNA MRD analysis in patients with localized bladder cancer. (A) Scatter plot of utDNA MRD levels (highest non-silent VAF per patient at preoperative time
point) after square root transformation for 3 groups: healthy adults, patients with pCR, and patients with no pCR. The p-values were calculated using Mann–Whitney U
test with α of 0.017 after Bonferroni correction. (B) ROC analysis classifying localized bladder cancer patients (either pCR or no pCR) versus healthy adults by utDNA
level. AUC and Youden index–optimized sensitivity and specificity values are shown. (C) Stacked bar plots showing the proportions of each group with positive or
negative utDNA MRD detection, determined using the optimal utDNA level threshold (VAF: 2.3%) that classified patients with no pCR from healthy adults. The p-values
were calculated using Fisher exact test with α of 0.017 after Bonferroni correction. (D) Multivariate logistic regression predicting the absence of pCR. The heatmap shows
logarithm of the OR for each variable in the logistic regression. Each bar shows a negative logarithm of the p-value, with the dashed line denoting α of 0.05. AUC, area
under the curve; MRD, minimal residual disease; OR, odds ratio; pCR, pathologic complete response; ROC, receiver operating characteristic; Sn, sensitivity; Sp, specificity;
Sqrt, square root; utDNA, urine tumor DNA; VAF, variant allele fraction; Y/N, yes/no.
https://doi.org/10.1371/journal.pmed.1003732.g003
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The association between pathologic response and utDNA remained highly significant when
restricting our analysis to MIBC patients treated first with neoadjuvant chemotherapy. An
ROC curve again showed that non-silent mutations (AUC = 0.84; 95% CI: 0.65 to 1.0) distin-
guish pCR from no pCR with higher accuracy than silent mutations (AUC = 0.55; 95% CI:
0.28 to 0.82) (S5A Fig). Moreover, patients with no pCR had a significantly higher utDNA
level than patients with pCR (2.4% versus 0%, p = 0.006) (S5B Fig). Using the same utDNA
threshold described above for the full cohort, 67% of patients with no pCR who received
neoadjuvant chemotherapy were utDNA MRD positive, while 100% of patients with pCR who
received neoadjuvant chemotherapy were utDNA MRD negative (S5C Fig). This difference in
the proportion of patients designated as utDNA MRD positive between each pathologic
response group was once again highly significant by Fisher exact test (p = 0.003). Notably,
stratifying patients who received neoadjuvant chemotherapy by pathologic staging also showed
a stepwise increase in detectable utDNA from ypT0N0 to ypTa/Tis N0 patients (S5D Fig).
Thus, a utDNA threshold trained to distinguish ypT0N0 from ypTa/Tis N0 disease has the
potential to be even more granular for detecting residual disease after neoadjuvant chemother-
apy in MIBC patients.
utDNA MRD as a prognostic biomarker
BC-1071 and BC-1206 are both MIBC patients who did not attain a pCR, and who, as
expected, had positive utDNA MRD detection on preoperative urine sample collection. BC-
1071 was a poor candidate for neoadjuvant chemotherapy and proceeded directly to radical
cystectomy (S6A Fig). utDNA MRD was detected at a high level of 10.1% with nonsynon-
ymous variation in the KLF5 coding region and a UTR mutation in TBC1D12.
Nonetheless, the oncology team deferred adjuvant therapy as the patient was felt to be a
poor candidate. Unfortunately, this patient developed metastasis to the liver 5.3 months after
surgery and passed away shortly thereafter. Similarly, BC-1206 proceeded directly to radical
cystectomy after oncologists considered this patient to be a suboptimal neoadjuvant chemo-
therapy candidate (S6B Fig). utDNA MRD was detected at a level of 2.8% with a stop–gain
mutation in TP53 and a nonsynonymous variation in the ARID1A coding region. Still, the
patient elected to undergo active surveillance after surgery, but, unfortunately, developed pro-
gressive disease just 1.5 months later with peritoneal and bowel metastases and died 5.4
months thereafter.
These clinical vignettes raised the question to us of how utDNA MRD detection compared
to pathologic response in terms of predicting clinical outcomes, such as PFS and OS. We thus
performed Kaplan–Meier analysis of patients in our cohort based on either utDNA MRD
detection or pathologic response for PFS and OS. Six patients in our cohort recurred within
200 days with a median time to recurrence of 148 days. Notably, all 6 of these early-relapsed
patients were utDNA MRD positive and exhibited significantly worse PFS compared to
utDNA MRD–negative patients (HR = 7.4; 95% CI: 1.4 to 38.9; p = 0.02) (Fig 4A). This effect
size was comparable to the PFS difference between patients with pCR compared to no pCR
(HR = 5.5; 95% CI: 1.1 to 28.1; p = 0.04) (Fig 4B), suggesting that utDNA MRD detection is on
par with pCR measured by a board-certified genitourinary pathologist in predicting PFS for
up 6 months after surgery. After 6 months, utDNA MRD detection may potentially be superior
to pathologic response, but more data are required to confirm this. Furthermore, utDNA
MRD detection (HR = 5.0; 95% CI: 0.7 to 37.6; p = 0.12) (S7A Fig) and pathologic response
(HR = 4.9; 95% CI: 0.6 to 37.2; p = 0.13) (S7B Fig) corresponded to differences in OS, but anal-
ysis of OS was not powered for statistical significance.
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Serial tracking of utDNA variants during neoadjuvant chemotherapy
We also correlated utDNA MRD detection with pathologic response for 2 patients (BC-1050
and BC-1045) who were treated with neoadjuvant chemotherapy and had multiple urine sam-
ples collected at different time points preceding radical cystectomy (S11 Table). We obtained
serial urine samples from these 2 patients prior to starting neoadjuvant chemotherapy, during
neoadjuvant chemotherapy, and on the day of radical cystectomy (MRD time point). All vari-
ants detected were monitored at each time point with CAPP-Seq using the previously
described approach [20,21,28].
Fig 4. Preoperative utDNA MRD as an early prognostic biomarker in localized bladder cancer patients. (A) Kaplan–Meier analysis of PFS stratified by preoperative
utDNA MRD detection and (B) pathologic response after radical cystectomy. utDNA MRD (+) patients had significantly worse PFS than utDNA MRD (−) patients
(HR = 7.4; 95% CI: 1.4–38.9; p = 0.02). Patients with no pCR also had significantly worse PFS than patients with pCR (HR = 5.5; 95% CI: 1.1–28.1; p = 0.04). HRs and p-
values were calculated using the Mantel–Haenszel and Mantel–Cox tests, respectively. (C) Serial urine cfDNA analysis for MIBC patient BC-1050. Imaging after
neoadjuvant chemotherapy was equivocal with residual bladder wall thickening. utDNA levels increased during neoadjuvant chemotherapy with a COSMIC- and
OncoKB-annotated nonsynonymous ERCC2mutation having the highest VAF. utDNA levels then decreased and became undetectable at the preoperative MRD time
point, concordant with pCR on surgical pathology. The patient remained disease free on long-term follow-up. (D) Serial urine cfDNA analysis for MIBC patient BC-
1045. Imaging after neoadjuvant chemotherapy noted decreased but persistent bladder wall thickening. utDNA levels decreased during neoadjuvant chemotherapy, with
a KMT2D stop–gain mutation having the highest VAF. utDNA levels then increased at the preoperative MRD time point with evidence of 2 new emergent
nonsynonymous mutations in ERBB2 and ARID1A, not present earlier. Consistent with this positive utDNA MRD result, the patient had pathological nodal
involvement despite achieving a pCR in the urothelium, and, less than a year later, developed progressive disease that prompted the start of treatment with atezolizumab.
cfDNA, cell-free DNA; CI, confidence interval; COSMIC, Catalogue of Somatic Mutations in Cancer; HR, hazard ratio; MIBC, muscle-invasive bladder cancer; MRD,
minimal residual disease; pCR, pathologic complete response; PFS, progression-free survival; utDNA, urine tumor DNA; VAF, variant allele fraction.
https://doi.org/10.1371/journal.pmed.1003732.g004
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BC-1050 is a MIBC patient treated with 4 cycles of dose-dense methotrexate, vinblastine,
doxorubicin, and cisplatin (Fig 4C). Surveillance imaging after neoadjuvant chemotherapy
continued to denote minimal bladder wall thickening, which was equivocal for reflecting treat-
ment response versus residual disease. utDNA MRD was not detected, however, suggesting a
complete tumor response to neoadjuvant chemotherapy. The patient proceeded to radical
cystectomy, where surgical pathology revealed pCR. The patient furthermore remained disease
free on longer-term follow-up. Thus, both pCR and disease-free survival corroborated the neg-
ative utDNA MRD result.
Strikingly, additional utDNA analysis of serial urine samples preceding the MRD time
point reflected changes in variant allele frequencies that were consistent with treatment
response (Fig 4C). Prior to starting neoadjuvant chemotherapy, 4 non-silent mutations were
detected with the highest being an ERCC2 nonsynonymous driver mutation, which has been
associated with increased response to chemotherapy [37,39]. Then, during chemotherapy
(before starting the second cycle), half of these mutations, including this same ERCC2muta-
tion, showed increased allele frequencies by an average of 5-fold relative to the initial measure-
ment. Two new mutations that were previously undetected before chemotherapy also emerged
at this time point during chemotherapy. However, these mutations all decreased significantly
and became undetectable at the MRD time point, reflecting a robust response to neoadjuvant
chemotherapy consistent with the pCR result. Thus, in retrospect, this patient represents an
intriguing candidate for future clinical trials testing utDNA as a means to personalize the dura-
tion of neoadjuvant chemotherapy and potentially optimize candidacy for bladder-sparing
treatment.
BC-1045 is another MIBC patient who was treated with 5 cycles of dose-dense gemcitabine
and cisplatin on a clinical trial, and the sixth cycle was held due to neuropathy and tinnitus
(Fig 4D). Surveillance imaging after chemotherapy noted a decrease, but not a complete disap-
pearance, of baseline bladder wall thickening. Imaging also never revealed suspicion for nodal
involvement. Preoperative utDNA MRD was detected, however, with the highest mutant allele
frequency being in KMT2D, which harbored a stop–gain mutation.
The patient went on to receive a radical cystectomy, and notably pathologic assessment
revealed no residual tumor in the bladder, suggesting a pCR in the urothelium (Fig 4D).
Nodal disease was identified in the surgical specimen, however, which had been missed in the
2 prior diagnostic imaging studies. On subsequent surveillance, the patient developed meta-
static left para-aortic lymphadenopathy within a year of surgery, which necessitated immune
checkpoint blockade. In this challenging diagnostic case where preoperative imaging and path-
ologic analysis of the urothelium could have been misleading, utDNA MRD analysis was able
to correctly identify nodal disease involvement and correlated with early disease progression
on follow-up. Thus, the presence of utDNA in this patient may have represented plasma-
derived transrenal cfDNA originating from disease outside the urothelium. This suggests that
our assay has the potential to detect nodal or distant disease in the absence of intravesical
disease.
For BC-1045, we also performed utDNA analysis of serial urine samples before and during
neoadjuvant chemotherapy (Fig 4D). Shortly after diagnosis and prior to any neoadjuvant che-
motherapy, the patient’s urine harbored non-silent mutations in PLEKHS1 and KMT2D, pres-
ent at variant allele frequencies of 1.9% and 4.9%, respectively. Interestingly, both of these
mutations decreased during neoadjuvant chemotherapy with their allele frequencies going
down by an average of 6.2-fold, consistent with the partial treatment response seen on imaging
following chemotherapy. However, utDNA analysis at the preoperative MRD time point
revealed a subsequent increase in the allele frequencies of these 2 mutations by an average of
5.2-fold, reflecting the development of treatment resistance, further highlighted by the
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emergence of newly detected mutations in ARID1A and ERBB2 since chemotherapy was initi-
ated. This patient represents a fascinating candidate for future clinical trials testing utDNA to
personalize the regimentation of neoadjuvant and adjuvant systemic treatment based on serial
utDNA analysis.
utDNA MRD oncogenomics for treatment personalization
Although neoadjuvant immunotherapy has been approved for frontline administration in cis-
platin-ineligible patients with metastatic bladder cancer, its use in the adjuvant setting is still
being validated with several large clinical trials currently underway [49–51]. We and others
have previously shown that TMB can be inferred from hybrid-capture cfDNA analysis in
patients with non-small cell lung or colorectal cancer [23,47,52]. To determine if similar meth-
odology can be applied to bladder cancer, we generated a linear regression model based on
whole exome sequencing of 409 MIBC tumors in TCGA and the corresponding non-silent
mutational burden detected by an expanded hybrid-capture panel for assessing TMB (Fig 5A,
S3 Table) [38]. From this correlation (Pearson’s r = 0.84, p< 0.001), we derived an equation
to infer exome-wide mutational burden from non-silent mutations in utDNA detected by our
TMB panel. Using this equation to infer TMB among utDNA MRD–positive patients in our
cohort (n = 24), the median TMB was 204 (range of 111 to 476) non-silent mutations per
exome (Fig 5B, S12 Table).
High TMB is predictive of response to immune checkpoint blockade based on data from
multiple studies in lung and bladder cancers [53,54]. A recent retrospective study of 139
patients with advanced, unresectable urothelial carcinoma receiving nivolumab on a clinical
trial (CheckMate 275) revealed that TMB categorization by tertiles, with the highest TMB ter-
tile defined as 170 missense mutations or more, was significantly associated with improved
objective response rate (ORR), PFS, and OS [55]. Given the prognostic potential of this high
TMB cutoff, we suggest that patients with an inferred TMB greater than 170 non-silent muta-
tions per exome may be classified as high TMB. Based on this cutoff, we hypothesize that 58%
of utDNA MRD–positive patients in our cohort with high urine–inferred TMB could poten-
tially be identified as candidates for adjuvant immunotherapy (Fig 5C), thus facilitating the
personalization of immune checkpoint blockade in the adjuvant setting for MIBC.
We also queried our cohort for potentially actionable mutations based on utDNA analysis,
which revealed that 13% of utDNA MRD–positive patients also harbor mutations that have
been shown to predict response to a drug in either bladder cancer or another solid tumor
malignancy type [45] (S8 Table). Potentially actionable mutations that we identified include
an ERCC2 nonsynonymous mutation that is indexed in both the Catalogue of Somatic Muta-
tions in Cancer (COSMIC) [56] and OncoKB [45] and correlates strongly with increased sensi-
tivity to cisplatin-based chemotherapy. Other potentially actionable mutations we identified
were nonsynonymous mutations in PIK3CA and TSC1, also annotated in both COSMIC [56]
and OncoKB [45], and shown to be clinically targetable in breast cancer through PI3K inhibi-
tion [57,58] and in central nervous system cancers with mTOR inhibition [59], respectively.
The remaining 42% of utDNA MRD–positive patients in our cohort harbored mutations
that were neither known to be actionable nor present at elevated burdens. We thus suggest
that these MRD–positive patients might be appropriate candidates for other types of adjuvant
therapy to ablate residual disease, such as chemotherapy or radiation therapy. Overall, the par-
adigm we describe in Fig 5C could thus form the basis for future clinical trials utilizing
utDNA-based personalization of adjuvant treatment for MIBC patients harboring MRD.
In this regard, we identified 2 utDNA MRD–positive patients with high urine–inferred
TMB in our cohort who received immunotherapy on a clinical trial. BC-1171 was randomized
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Fig 5. utDNA MRD as a biomarker for adjuvant treatment personalization. (A) Comparison of non-silent mutational load detected by whole exome sequencing and
uCAPP-Seq for MIBC cases in TCGA (n = 409), using an expanded gene panel for assessing TMB (referred to as the TMB panel; S3 Table). Linear regression was
performed (Pearson’s r = 0.84; equation shown) to interpolate exome-wide TMB based on the number of non-silent mutations detected by uCAPP-Seq. (B) Scatter plot
depicting inferred TMB among patients with positive utDNA MRD in our cohort with the median indicated by a horizontal black line. (C) Potential adjuvant treatment
strategies for utDNA MRD (+) patients based on urine-inferred TMB. (D) Vignette depicting MIBC patient BC-1171 who was utDNA MRD (+) at the preoperative time
point, concordant with no pCR on surgical pathology with evidence of locally advanced pT3a disease (AJCC 8). Six non-silent mutations were detected in preoperative
urine from this patient as indicated. Urine-inferred TMB was elevated at 204. This patient was randomized to pembrolizumab on a clinical trial and has shown no
evidence of disease on long-term follow-up, consistent with our prediction for a patient with high inferred TMB. AJCC 8, American Joint Committee on Cancer 8th
edition; MIBC, muscle-invasive bladder cancer; MRD, minimal residual disease; pCR, pathologic complete response; TCGA, The Cancer Genome Atlas; TMB, tumor
mutational burden; TURBT, transurethral resection of bladder tumor; tx, treatment; uCAPP-Seq, urine Cancer Personalized Profiling by Deep Sequencing; utDNA, urine
tumor DNA.
https://doi.org/10.1371/journal.pmed.1003732.g005
PLOS MEDICINE Urine tumor DNA detection of MRD in muscle-invasive bladder cancer treated with radical cystectomy
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003732 August 31, 2021 20 / 30
to adjuvant treatment with pembrolizumab after radical cystectomy (Fig 5D). This patient har-
bored an inferred TMB of 204 mutations per exome, thus classifying this patient as high TMB
using our criteria. This patient has shown no evidence of recurrence or progression since sur-
gery, which is consistent with our prediction based on our proposed paradigm. BC-1045, who
was discussed previously (Fig 4D), was randomized to the observation arm of this same trial
(versus pembrolizumab). The patient was diagnosed with disease progression 10.2 months fol-
lowing surgery and thus enrolled onto a different trial, where they are receiving treatment with
single-agent atezolizumab. With an elevated urine-inferred TMB of 340 mutations per exome
at the preoperative MRD time point, this patient has achieved a radiographic complete
response in the involved lymph nodes on atezolizumab. It is tempting to speculate that this
patient with high utDNA–inferred TMB may have averted disease relapse altogether if offered
immunotherapy shortly after the MRD time point.
Discussion
Here we present a cohort study that demonstrates the significant correlation between utDNA
MRD detected by uCAPP-Seq prior to curative-intent radical cystectomy and pathologic
response determined by analysis of the surgical specimen. We demonstrated this by utDNA
analysis with a focused gene panel of non-silent mutations in consensus driver genes, which
indicates that association with pathologic response is strongly linked to the detection of muta-
tions that impact the phenotype of bladder cancer and are less likely to be confounded by back-
ground field effect [18,46]. As expected, the most commonly mutated genes detected in urine
cfDNA in our cohort were TERT and TP53, consistent with the results of larger tumor
sequencing studies [18,38,39]. Our approach also demonstrates an 85% level of concordance
among mutations detected between tumor and utDNA for the subset of patients with tumor
tissue available for analysis. Of note, our MRD detection approach only utilizes mutations with
duplex support, which facilitates the low limit of detection necessary for MRD detection [21].
It also does not require prior sequencing of tumor tissue, which is practically useful and bio-
logically can help avoid confounding of results due to geographic tumor heterogeneity [22].
Targeted NGS has previously been applied to detect early-stage bladder cancer in reason-
ably large cohorts using methods including UroSEEK [60] and uCAPP-Seq [28]. utMeMa, a
methylation-based assessment of utDNA, has also shown feasibility in the MRD setting [61].
However, these previous urine-based sequencing approaches were either largely restricted to
or exclusively studied in NMIBC and did not corroborate residual disease detection with a rad-
ical cystectomy specimen, which is currently the most accurate assessment of residual disease
after standard of care treatment for MIBC. Moreover, there are several key differences in the
biology and prognosis of NMIBC and MIBC, as the latter often arises via progression of
urothelial dysplasia to muscle-invasive disease due to the accumulation of genomic alterations
[62]. This is potentially related to an exacerbated field cancerization effect that may increase
the risk of advanced disease and is associated with higher levels of nonspecific genomic alter-
ations [63]. These distinctions require important technological advancements that optimize
variant calling for MIBC.
In our study, we focused predominantly on MIBC with every patient being treated with
radical cystectomy as part of their clinical management. Moreover, given that our cohort was
predominantly composed of muscle-invasive patients, a high percentage received neoadjuvant
chemotherapy. In this regard, we were able to apply state-of-the-art targeted deep sequencing
using uCAPP-Seq technology to identify duplex-supported variants and analyze MRD in an
important population not thoroughly assessed previously. Moreover, we correlated our find-
ings with gold standard clinical outcomes including pathologic response, PFS, and OS.
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Our data suggest that utDNA MRD detection can accurately predict pathologic response in
MIBC patients. Predicting pathologic response in this fashion could enable personalization of
treatment decisions for MIBC patients in the future. For example, utDNA MRD detection sta-
tus could help inform bladder-sparing treatment, potentially enabling clinicians to forego radi-
cal cystectomy altogether in selected patients found to be MRD negative. Conversely, patients
found to be utDNA MRD positive could be prioritized for further treatment such as targeted
or immune therapy, which we suggest could be personalized based on the oncogenomic fea-
tures learned from utDNA analysis. Notably, we did not detect any activating mutations in
FGFR3 in our cohort, which have been shown to predict responses to tyrosine kinase inhibi-
tors in bladder cancer [64]. For example, erdafitinib is an FGFR inhibitor that is FDA approved
for use in patients with locally advanced or metastatic bladder cancer [65]. Therefore, in addi-
tion to the mutations we highlighted in our cohort, utDNA could have the potential to enable
personalized systemic treatment with erdafitinib for patients harboring FGFRmutations in the
near future.
We additionally show through clinical vignettes that monitoring of utDNA before, during,
and after neoadjuvant chemotherapy can be used to temporally monitor treatment response
versus the emergence of resistance. Using this type of temporally high-resolution utDNA anal-
ysis, we envision that the strength and regimentation of neoadjuvant treatment could be fur-
ther optimized, along with the consideration and timing of radical cystectomy. utDNA could
also be used as an adjunct to other emerging modalities in this regard, such as VI-RADS, a
newly developed MRI-based staging criteria [66], to more definitively predict treatment
response and clinical outcomes in the future.
Limitations of our study include that utDNA analysis was performed considering only
SNVs, which are the most predominant genomic alterations observed in bladder cancer
[38,67], a cancer type with among the highest SNV burdens overall [68]. Importantly, since a
false negative (i.e., no pCR falsely identified as utDNA MRD negative) could potentially result
in a fatal outcome if used to guide clinical decision-making, our assay is not yet useful for rou-
tine clinical application. Additionally, the findings we present here will need to be indepen-
dently validated before clinical implementation. As the tumor genomic characterization of
MIBC broadens in the future, the sensitivity of our assay should improve. Future work to
improve the sensitivity of residual disease detection could also explore the combination of
utDNA analysis with clinical evaluation (i.e., cystoscopy), as well as incorporating other geno-
mic alterations into our method (e.g., copy number variations, insertions/deletions, and
fusions).
We also note that all utDNA testing in this study was performed prior to radical cystectomy,
which enabled us to assess the ability of utDNA MRD to predict pathologic response. How-
ever, utDNA analysis at this time point makes it challenging to assess potential subsequent
prognostic implications, since the risk of disease progression or death is typically diminished
by curative-intent surgical intervention [2]. As a result, a utDNA MRD–positive patient at ele-
vated risk of disease progression could have their MRD fully addressed via surgery, and, thus,
could remain disease free in our Kaplan–Meier analysis. Even with this limitation, however,
we observed a significant difference in PFS and likely a difference in OS. An ongoing prospec-
tive clinical trial utilizing a multi-institutional cohort through the Alliance study
(NCT03609216) will aim to further validate the ability of utDNA to predict complete response
and survival outcomes. Future work may also include studying a cohort of healthy smokers in
order to examine if utDNA can be used as a screening tool for bladder cancer.
Finally, it has been shown that mutations in DNA damage repair genes, such as ERCC2, are
predictive of chemotherapeutic response [37,39]. This is consistent with our observation of an
overall decrease in variant allele frequencies in serial urine samples collected during and after
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neoadjuvant chemotherapy for patient BC-1050, who harbored a nonsynonymous ERCC2
mutation. Still, we were unable to assess the association between DDR mutations and chemo-
therapeutic response in our cohort as a whole because these mutations at the MRD time point
are mostly undetectable after chemotherapy is complete, as was the case for BC-1050. To
increase the number of mutations detected in DNA damage repair genes, we would need to
increase our study power by enrolling more patients or preferably collect and analyze more
urine samples prior to neoadjuvant chemotherapy.
In conclusion, we have shown that utDNA MRD detection with uCAPP-Seq classifies path-
ologic response with high sensitivity and specificity in a cohort comprised predominantly of
MIBC. Our approach has the potential to facilitate more personalized treatment interventions
for MIBC in the future, such as curative-intent bladder-sparing approaches, adjuvant treat-
ment with immune checkpoint blockade, and targeted systemic therapy administration. To
establish clinical utility, these utDNA-guided interventions will need to be assessed in prospec-
tive clinical trials.
Supporting information
S1 Checklist. STROBE Statement—Checklist of items that should be included in reports of
cohort studies. STROBE, Strengthening the Reporting of Observational Studies in Epidemiol-
ogy.
(DOCX)
S1 Fig. EDTA prevents urine cfDNA degradation. Technical experiment to evaluate the sta-
bility of urine cfDNA with and without the addition of EDTA. Pooled urine from a healthy
volunteer was stored for 7 days with versus without 10 mM EDTA at room temperature. Urine
cfDNA was extracted at days 0, 1, 3, and 7 after commencing storage. The effect of EDTA on
urine cfDNA degradation was evaluated based on the percentage of DNA in the 70–450 bp
size range on Bioanalyzer eletropherogram. The data presented here are mean ± SEM of 2 rep-
licates per time point. The p-value was calculated by unpaired Student t test at the last time
point. bp, base pair; cfDNA, cell-free DNA; SEM, standard error of the mean.
(TIF)
S2 Fig. Schema for comparing in vitro size selection against acoustic fragmentation of
urine cfDNA. Representative electropherograms are also shown, all from the same MIBC
patient’s urine sample. bp, base pair; cfDNA, cell-free DNA; MIBC, muscle-invasive bladder
cancer; mM, millimolar; uCAPP-Seq, urine Cancer Personalized Profiling by Deep Sequenc-
ing.
(TIF)
S3 Fig. Comparison of acoustic whole urine cfDNA fragmentation to in vitro size selection
of 70–450 bp cfDNA fragments. (A) Median deduplicated sequencing depths, (B) Number of
non-silent mutations, (C) Mutant allele fraction levels in 4 MIBC urine cfDNA samples that
underwent in vitro size selection or acoustic DNA fragmentation (see S2 Fig for schema). Data
values are depicted as points, column heights represent averages, and error bars represent stan-
dard error of the mean. VAF comparisons in (C) are also shown with connecting lines. The p-
values were calculated using the paired Student t test method. bp, base pair; cfDNA, cell-free
DNA; MIBC, muscle-invasive bladder cancer; VAF, variant allele fraction.
(TIF)
S4 Fig. ROC analysis classifying pCR versus no pCR with different variant calling criteria.
The red curve shows variant calling of non-silent, duplex-supported mutations in the MRD
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panel. The blue curve shows variant calling of non-silent, duplex-supported mutations in the
TMB panel. The green curve shows variant calling of all mutations (silent or non-silent) with
duplex support in the TMB panel. The AUC, as well as the optimal sensitivity and specificity
values corresponding to Youden J statistic, is shown. AUC, area under the curve; MRD, mini-
mal residual disease; pCR, pathologic complete response; ROC, receiver operating characteris-
tic; Sn, sensitivity; Sp, specificity; TMB, tumor mutational burden.
(TIF)
S5 Fig. utDNA MRD analysis in MIBC patients treated with neoadjuvant chemotherapy.
(A) ROC analysis classifying MIBC patients (either pCR or no pCR) who received neoadjuvant
chemotherapy before radical cystectomy based on non-silent versus silent mutations detected
in preoperative urine cfDNA. The AUC, as well as the optimal sensitivity and specificity values
corresponding to Youden J statistic, is shown. (B) Scatter plot of utDNA levels (highest non-
silent VAF per patient at the preoperative time point) after square root transformation in
patients who achieved pCR versus those with no pCR following neoadjuvant chemotherapy.
The p-value was calculated using Mann–Whitney U test. (C) Stacked bar plots showing pro-
portions of each group with positive or negative utDNA MRD detection after neoadjuvant
chemotherapy, determined by the optimal utDNA threshold (VAF: 2.3%) that classified
patients with no pCR from healthy adults in the full patient cohort as described in the Meth-
ods. The p-value was calculated using Fisher exact test. (D) Scatter plot of utDNA levels after
square root transformation in patients who received neoadjuvant chemotherapy, grouped by
pathologic stage. Column heights depict mean values, and error bars represent the standard
error of the mean. The Kruskal–Wallis H statistic and p-value are shown in the upper left.
There were no patients with ypT1 disease. AUC, area under the curve; cfDNA, cell-free DNA;
MIBC, muscle-invasive bladder cancer; MRD, minimal residual disease; pCR, pathologic com-
plete response; ROC, receiver operating characteristic; Sn, sensitivity; Sp, specificity; Sqrt,
square root; utDNA, urine tumor DNA; VAF, variant allele fraction.
(TIF)
S6 Fig. Correlation of utDNA MRD detection with pathologic nonresponse in 2 MIBC
patients. (A) Clinical vignette of MIBC patient BC-1071 who was utDNA MRD (+) at the pre-
operative time point with a utDNA level of 10.1%, which was concordant with no pCR on sur-
gical pathology. The patient progressed 160 days later and died shortly thereafter. (B) Clinical
vignette of MIBC patient BC-1206 who was utDNA MRD (+) at the preoperative time point
with a utDNA level of 2.8%, which was concordant with no pCR on surgical pathology. The
patient progressed at 46 days after radical cystectomy, received chemoradiation to treat the
recurrence, but, nonetheless, died at 164 days. MIBC, muscle-invasive bladder cancer; MRD,
minimal residual disease; pCR, pathologic complete response; TURBT, transurethral resection
of bladder tumor; utDNA, urine tumor DNA.
(TIF)
S7 Fig. Correlation of utDNA MRD detection and pathologic response with OS. OS analy-
sis according to utDNA MRD detection at the preoperative time point (A) and pathologic
response assessed in the radical cystectomy specimen (B). HRs and p-values were calculated
using the Mantel–Haenszel and Mantel–Cox methods, respectively. CI, confidence interval;
HR, hazard ratio; MRD, minimal residual disease; OS, overall survival; pCR, pathologic com-
plete response, utDNA, urine tumor DNA.
(TIF)
S1 Table. Patient-level characteristics in the bladder cancer cohort.
(XLSX)
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S2 Table. Genes fully or partially covered in the MRD panel. MRD, minimal residual dis-
ease.
(XLSX)
S3 Table. Genes fully or partially covered in the TMB panel. TMB, tumor mutational bur-
den.
(XLSX)
S4 Table. Sequencing metrics of urine cfDNA for all patients. cfDNA, cell-free DNA.
(XLSX)
S5 Table. Sequencing metrics of urine cfDNA in healthy adults. cfDNA, cell-free DNA.
(XLSX)
S6 Table. Tumor tissue and germline DNA sequencing metrics.
(XLSX)
S7 Table. Mutational concordance between tumor tissue and urine cfDNA. cfDNA, cell-
free DNA.
(XLSX)
S8 Table. Mutations detected at the preoperative MRD time point in urine using the MRD
panel. MRD, minimal residual disease.
(XLSX)
S9 Table. Characteristics of patients according to pathologic response at surgery.
(XLSX)
S10 Table. Multivariate logistic regression to predict the absence of pathologic complete
response.
(XLSX)
S11 Table. Serial monitoring of utDNA on neoadjuvant chemotherapy. utDNA, urine
tumor DNA.
(XLSX)
S12 Table. Urine-inferred tumor mutational burden for utDNA MRD positive patients.
MRD, minimal residual disease; utDNA, urine tumor DNA.
(XLSX)
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